Prof David Mirelman

"Not for Profit" offers an inside look at the challenges and successes in transforming scientific discoveries into real world applications. Israel's Weizmann Institute of Science has become a world model for the Technology Transfer process, a mechanism set in motion more than 80 years ago by the Institute's founder, Dr. Chaim Weizmann, who conducted basic scientific research while enabling key discoveries to make their way to the market place.Weizmann scientists are engaged in curiosity-driven research and their investigations sometimes lead to unexpected discoveries. Yeda Com., the Institute's technology transfer arm, patents and licenses inventions of Weizmann scientists and licenses the rights to develop and sell products, based on the invention, to commercial companies . During the years, quite a number of these licenses have resulted in becoming blockbuster drugs such as Copaxone, Erbitux, Rebif, Avonex, Enbrel, Humira, Remicade and Vectibix which are marketed and sold worldwide by large Pharma companies. In addition, Institute mathematicians and computer scientists have developed novel encryption and decoding algorithms which are nowadays the world standard systems for satellite encoded TV programs as well for Bank financial transfers and credit cards. The Book author, Prof. David Mirelman is a veteran Weizmann scientist and a former longtime Chairman of Yeda who also served as the Institute's Vice President for Technology Transfer . The author makes a powerful case for ensuring the independence and integrity of basic research at Universities and Academic Institutions and offers insights into ways to resolving commercial and conflict of interest disputes which occurred during his watch. The book is an important read for anyone interested in high-tech, biotech and in the complex process of funding and translating innovation into growth. Prof. Mirelman has an M.Sc. in Chemistry from the Hebrew University in Jerusalem and a PhD in Biochemistry from the Weizmann Institute. He did postdoctoral studies at Tufts University Medical School in Boston and spent sabbaticals as visiting scientist at the Max Planck Institute in Tuebingen Germany , at U.C. Berkeley in California. and as a Fogarty Scholar in Residence at the National Institutes of Health in Bethesda, Maryland . He investigated the mode of action of antibiotics , mechanisms of antibiotic resistance in microorganisms and molecular mechanisms of toxins of pathogenic microorganisms and human parasites in the digestive tract. He has published more that 240 articles in major international scientific journals. Today he is an Emeritus Professor at the Weizmann Institute and continues to actively pursue his research.

Published February 17, 2020

MY ACCOUNT

Products

Not for Profit: The Business of Academic Scientific Research

Not for Profit: The Business of Academic Scientific Research

Follow Us On Social: